从原子能量转移模拟中对人类血清白蛋白的连接键的表征
Özge Ergün1,2, Andrea Bertran-Mostazo1,3, Elena Cubero4
1Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Barcelona, 08028, Spain.
Small methods
|November 14, 2025
概括
这项研究引入了一种新的协议,将光谱学和原子模拟相结合,以准确识别蛋白质结合部位和连接物协调. 该方法克服了对于蛋白质-连接体复合体的福斯特共振能量转移 (FRET) 的局限性.
科学领域:
- 生物物理学的生物物理.
- 计算化学计算化学
- 结构生物学 结构生物学
背景情况:
- 福斯特共振能量转移 (FRET) 对于测量生物分子系统中的距离至关重要.
- 传统的FRET应用在蛋白质连接体复合体上受到染色体定向和点双极近似偏差的限制.
- 精确地描述蛋白质 - 配体相互作用对于药物发现至关重要.
研究的目的:
- 开发和验证一种新的协议,用于在现场识别结合点和连接体协调模式.
- 为了克服FRET在研究蛋白质 - 连接体复合物的固有局限性.
- 为了在生物物理研究中实现更准确的距离估计和具有约束力的模型歧视.
主要方法:
- 使用TrESP-MMPol模型将光谱与高效的原子模拟集成在一起.
- 在可偏振的经典环境中利用电静电潜力配备的过渡电荷.
- 适用于具有光小分子图书馆的人类血清白蛋白 (HSA).
主要成果:
- 准确地复制了纳普罗,卡普罗和印莫他对HSA的已知结合点.
- 确定其他小分子的新型结合场景.
- 证明模拟可观测物可以区分可信的绑定模型,包括位置和模式.
结论:
- 开发的协议有效地克服了FRET的方向和介电选假设.
- 将实验FRET数据与原子模拟进行直接比较,可以准确地确定结合部位和模式.
- 该协议适用于单个托残留的目标,并可通过现场标签扩展到其他药物发现目标.
相关概念视频
02:18The Equilibrium Binding Constant and Binding Strength
14.8K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
14.8K
02:18The Equilibrium Binding Constant and Binding Strength
9.9K
9.9K
02:40Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
01:29Drug Distribution: Plasma Protein Binding
8.3K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.3K
00:49Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
01:30Drug Binding to Blood Components
483
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
483